Short Term Trading Week Starting: 29 Oct, page-34

GMV up 30% on  good announcement

ASX RELEASE: 30 October 2018 ASX: GMVCE, FDA & CFDA Approval Granted for Guangzhou China Production Facility• CE, FDA and CFDA approval granted for the Company’s Guangzhou China ProductionFacility• Allows for major increase to the Company’s global production capacityMobile and e-Health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”)(ASX: GMV) is pleased to announce it has successfully completed the independent audit process toachieve CE, FDA and CFDA regulatory approval for the Company’s Production Facility in GuangzhouChina.The Company is proud to inform its shareholders that it achieved excellent results during the multistageindependent audit process conducted during September and October for all three regulatorybodies (CE, FDA and CFDA). The full audit has now been completed, and the results of the audit areexpected to be published and searchable to the public later this week via the following directory;https://www.sgsgroup.com.cn/en/certified-clients-and-products/certified-client-directoryThe Company expects to receive its final certification documentation from the Regulatory bodieswithin 3 weeks. This is a significant milestone for the Company which intends to utilise the fullproduction capacity of its Guangzhou facility.As previously announced to the market, the Company has numerous agreements in place globallyand the approvals granted for the Guangzhou Facility enables the Company to commenceproduction and distribution to those territories which recognise CE, FDA and CFDA certification andhave already granted regulatory approval for the Company’s medical devices.G Medical CEO Dr. Yacov Geva said, “We are very pleased to have achieved CE, FDA and CFDAapproval, which exemplifies the high-quality of our Production Facility and our strong in-Countryrelationships. The Company has been committed to achieving this major milestone in recordtimeframes and we now look forward to being able to meet the demand from our globalpartnerships and rapidly execute our commercial plans.”G Medical has a strong pipeline of customer demand and the increased production capacitypositions the Company to fulfil its expansion into the rapidly growing E-Health market. As theCompany continues its preparations for the listing of its Chinese subsidiary, Guangzhou YimeiInnovative Medical Science and Technology Co. Ltd, on the main board of The Hong Kong StockExchange (HKSE), the granting of CE, FDA and CFDA approval was an important achievement in thisprocess.